成人RSV住院不良结局风险的多中心英国队列研究
该研究汇总三个英国成人RSV住院队列，纳入334例PCR确诊患者，主要结局为60天内ICU/HDU入住或全因死亡。仅按年龄≥75岁分层的区分度有限（AUC 0.58），而包含年龄、COPD、肿瘤和痴呆的四预测因子模型区分度更高（AUC 0.77），提示基于合并症的风险分层可能更有价值。
要点
- 住院成人RSV患者中，单纯年龄≥75岁对不良结局的区分能力有限。
- 包含COPD、肿瘤和痴呆的四预测因子模型区分度更高，AUC达0.77。
- 合并症模型在5%–20%决策阈值下净获益更大，但需外部验证。
核心结论
- 在因RSV相关急性呼吸道感染住院的成人中，单纯基于年龄（包括英国≥75岁疫苗标准）的风险分层区分度有限。
- 包含合并症的四预测因子模型可能提供更有信息量的住院风险分层，值得在未来的RSV疫苗效果和结局研究中评估。
研究设计与样本
- 汇总三个英国医院队列（一个前瞻性、两个回顾性）的成人急性呼吸道感染且PCR确诊RSV的住院患者。
- 共纳入334例成人，主要结局为60天内ICU/HDU入住或全因死亡。
主要发现
- 334例中37例（11.1%）发生主要结局。
- 仅按年龄≥75岁规则的乐观校正AUC为0.58（95%CI 0.48–0.65），预测风险分布压缩。
- 四预测因子模型（年龄、COPD、活动性/既往肿瘤、痴呆）的AUC为0.77（95%CI 0.69–0.85），预测风险分布更宽。
关键数值与推荐
- 年龄≥75岁规则模拟英国当前疫苗年龄资格，其乐观校正AUC为0.58（95%CI 0.48–0.65）。
- 四预测因子模型AUC为0.77（95%CI 0.69–0.85），在5%–20%临床升级阈值下净获益最大。
临床怎么用
- 住院RSV成人不宜仅凭年龄≥75岁进行风险分层。
- 可考虑结合COPD、肿瘤和痴呆等合并症评估不良结局风险。
- 该模型需外部验证、更系统的RSV检测及与生理评分比较后才可用于临床。
局限性
- 任何应用均需外部验证。
- 需要更系统的RSV检测。
- 需在更大规模、已接种疫苗的队列中与基于生理指标的评分进行比较。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
Background Respiratory syncytial virus (RSV) causes substantial winter pressure on adult services. In the UK, RSV vaccination currently targets adults aged ≥75 years and care home residents; it remains uncertain whether this age criterion alone meaningfully discriminates risk of poor outcome among adults hospitalised with RSV. Methods We pooled three UK hospital cohorts (one prospective, two retrospective) of adults admitted with acute respiratory infection (ARI) and PCR-confirmed RSV. The primary outcome was intensive care unit/high dependency unit (ICU/HDU) admission or all-cause mortality within 60 days. Prespecified predictors (age, sex and comorbidities) entered a least absolute shrinkage and selection operator (LASSO) penalised logistic regression; selected variables were refitted using standard logistic regression. Discrimination, calibration and decision-analytic performance were assessed using 1000-bootstrap internal validation and decision-curve analysis. Results Among 334 adults, 37 (11.1%) experienced the primary outcome. An age-only rule mirroring current UK vaccine age-eligibility (≥75 years) demonstrated only modest discrimination (optimism-adjusted area under the receiver operating characteristic curve (AUC) 0.58, 95% CI 0.48 to 0.65) and a compressed distribution of predicted risks. A four-predictor model—including age, COPD, active/previous cancer and dementia—achieved higher discrimination AUC (0.77 (0.69 to 0.85)), a wider spread of predicted risks and the greatest net benefit across clinically plausible escalation thresholds (5–20%). Conclusions In adults hospitalised with RSV-associated ARI, simple age-based heuristics—including the UK ≥75-year threshold—showed only modest ability to discriminate risk of ICU/HDU admission/60-day mortality once hospitalised. Comorbidity-inclusive approaches may provide more informative hospital-level risk stratification and warrant evaluation in future RSV vaccine-effectiveness and outcome studies. Any application requires external validation, more systematic RSV testing and comparison with physiology-based scores in larger, vaccinated cohorts.
引用
- Thorax：Understanding risk of poor outcomes in adults hospitalised with respiratory syncytial virus infection: evidence from a multicentre UK cohort
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。